Clinical

Risk factors and prostate-specific antigen are both important when determining how to move forward with treatment, explained Angela Jia, MD, PhD, of University Hospitals and Case Western Reserve University School of Medicine.

Physicians treated the patient without surgery, although they said the patient’s case is particularly challenging and treatment was ongoing at the time of the report’s writing.

Innovation in the specialty pipeline, drug costs, health care policy updates, and collaboration were key topics at this year's Asembia Specialty Pharmacy Summit.

With more therapies available in bladder, kidney, and prostate cancers, collaboration among health care providers can help ensure patients are getting the most appropriate care for their type and stage of cancer, said Mary Dunn, MSN, NP-C, OCN, RN, of University of North Carolina.

Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.

Survey results from more than 1500 patients with diabetes revealed that 57% believed glucagon-like peptide-1 (GLP-1) weight loss drugs alone could be a "silver bullet" for managing their health goals.

The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.

The novel intravesical drug delivery system releases erdafitinib locally within the bladder while limiting systemic toxicities.

Patients with small or slow-growing tumors or those with comorbidities that make them higher risk are likely better candidates for active surveillance, explained Yuzhi Wang, MD, of Henry Ford Health Vattikuti Urology Institute.

Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.

According to a review, recent progress offers hope in the form of treatments, such as combination therapy that utilizes surgical and nonsurgical methods, for individuals with facial acne scars.

Updated findings from SunRISe-1 also showed that all but 1 responder achieved complete response within 12 weeks of treatment with the targeted gemcitabine delivery system.

Lower rates of cardiac surgery were found in patients living with HIV along with an increased risk of adverse events.

A retrospective analysis suggested that immune cells play a role in the progression of paroxysmal nocturnal hemoglobinuria (PNH).

Speakers discussed the disparities in prostate-specific antigen (PSA) screening rates among different racial groups and explored the potential of free PSA percentage as a predictive marker for future prostate cancer risk.

Lower antioxidant intake is associated with an increased risk of rheumatoid arthritis (RA) in women of childbearing age with endometriosis (EM), highlighting the importance of antioxidant intake for managing EM-related RA.

In this interview, Chris Pagnani, MD, PC, shares how telemedicine is transforming mental health care by making psychiatry accessible for patients, especially for those in health care deserts.

Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point.

Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.

More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.

Blood-based screening for colorectal cancer (CRC) should only be used with patients who are not completing other endorsed screening options, according to a study.

In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.

Data highlight substantial improvements in outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) among older patients with acute myeloid leukemia (AML).

A predictive model using plasma proteins as biomarkers predicted hepatocellular carcinoma development more accurately than a model based on traditional lifestyle risk factors in a recent study.

Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.

A new definition of rectal cancer in the Netherlands prompted reclassification of cancer as sigmoid tumors, which could lead to better treatment.

Data from the study showed that exa-cel prevented vaso-occlusive crises in all but 1 of the 30 evaluable patients for at least 12 months.

Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.

In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.

Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.